Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Repurposing Celecoxib to Overcome Resistance to Immunotherapy in Advanced HCC (RECON Study)

NCT07174570 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT07174570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07174570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Repurposing Celecoxib to Overcome Resistance to Immunotherapy in Advanced HCC (RECON Study)
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Recruiting
Start date
January 2, 2026
Completion date
November 13, 2027
Enrollment
39 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma, metastatic hepatocellular carcinoma, stage iii hepatocellular carcinoma ajcc v8, stage iv hepatocellular carcinoma ajcc v8